Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLO-501 and ALLO-647 in R/R LBCL or Follicular Lymphoma
NCT03939026Phase 1Completed
- Sponsor
- Allogene Therapeutics
- Start
- May 2019
- Primary completion
- Oct 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UCART-19 in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by Allogene Therapeutics. Primary endpoints: Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of ALLO-501 at 28 days and Proportion of patients experiencing Dose Limiting Toxicity with ALLO-647 in combination with fludarabine/cyclophosphamide administered prior to ALLO-501 at 33 days. Started May 2019; status: completed.
02
Drugs
UCART-19
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03939026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03939026.